MorphoSys Future Growth

Future criteria checks 2/6

MorphoSys is forecast to grow earnings and revenue by 67.3% and 24.6% per annum respectively while EPS is expected to grow by 77.9% per annum.

Key information

67.3%

Earnings growth rate

77.9%

EPS growth rate

Biotechs earnings growth	31.2%
Revenue growth rate	24.6%
Future return on equity	n/a
Analyst coverage	Good
Last updated	30 Apr 2024

Recent future growth updates

Recent updates

MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%

Apr 17

MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be

Nov 26

Earnings and Revenue Growth Forecasts

XTRA:MOR - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	425	-31	-120	-50	5
12/31/2025	325	-116	-258	-226	9
12/31/2024	123	-430	-296	-253	1
3/31/2024	241	-469	-286	-284	N/A
12/31/2023	238	-190	-299	-296	N/A
9/30/2023	223	104	-363	-355	N/A
6/30/2023	255	100	-349	-338	N/A
3/31/2023	261	-61	-321	-306	N/A
12/31/2022	278	-151	-382	-367	N/A
9/30/2022	250	-861	-436	-417	N/A
6/30/2022	195	-851	-606	-588	N/A
3/31/2022	174	-596	-610	-583	N/A
12/31/2021	180	-514	-508	-481	N/A
9/30/2021	163	-150	-423	-393	N/A
6/30/2021	143	-103	-295	-246	N/A
3/31/2021	124	-177	-255	-217	N/A
12/31/2020	328	98	-14	35	N/A
9/30/2020	303	64	26	63	N/A
6/30/2020	293	105	98	113	N/A
3/31/2020	309	153	137	152	N/A
12/31/2019	72	-103	-85	-81	N/A
9/30/2019	71	-96	-68	-64	N/A
6/30/2019	114	-42	-42	-39	N/A
3/31/2019	87	-59	-33	-31	N/A
12/31/2018	76	-56	-35	-33	N/A
9/30/2018	94	-27	-16	-14	N/A
6/30/2018	54	-82	-61	-48	N/A
3/31/2018	58	-74	-68	-55	N/A
12/31/2017	67	-70	N/A	-38	N/A
9/30/2017	52	-84	N/A	-52	N/A
6/30/2017	49	-73	N/A	-59	N/A
3/31/2017	49	-68	N/A	-47	N/A
12/31/2016	50	-60	N/A	-47	N/A
9/30/2016	49	-45	N/A	-48	N/A
6/30/2016	48	-40	N/A	-41	N/A
3/31/2016	48	-33	N/A	-35	N/A
12/31/2015	106	15	N/A	-24	N/A
9/30/2015	111	27	N/A	-15	N/A
6/30/2015	116	33	N/A	-3	N/A
3/31/2015	119	37	N/A	-4	N/A
12/31/2014	64	-3	N/A	-14	N/A
9/30/2014	61	-6	N/A	-15	N/A
6/30/2014	60	-5	N/A	79	N/A
3/31/2014	77	7	N/A	76	N/A
12/31/2013	78	7	N/A	89	N/A
9/30/2013	80	14	N/A	100	N/A
6/30/2013	76	16	N/A	3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MOR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MOR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MOR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MOR's revenue (24.6% per year) is forecast to grow faster than the German market (5.2% per year).

High Growth Revenue: MOR's revenue (24.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MOR's Return on Equity is forecast to be high in 3 years time

MorphoSys Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 167%

Consensus EPS estimates upgraded to €3.87 loss, revenue downgraded

Price target increased by 13% to €35.50

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

Consensus EPS estimates fall by 12%, revenue upgraded

Price target decreased by 8.7% to €31.78

Recent updates

MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index

MorphoSys AG Announces Board Changes

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

New major risk - Negative shareholders equity

Consensus EPS estimates fall by 167%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Would MorphoSys (ETR:MOR) Be Better Off With Less Debt?

Consensus EPS estimates upgraded to €3.87 loss, revenue downgraded

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Profitability

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Price target increased by 13% to €35.50

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 16%

New minor risk - Shareholder dilution

MorphoSys AG's (ETR:MOR) 93% Share Price Surge Not Quite Adding Up

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Investor sentiment improves as stock rises 43%

Consensus EPS estimates fall by 12%, revenue upgraded

Price target decreased by 8.7% to €31.78

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 17%

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Investor sentiment improves as stock rises 16%

Morphosys AG Provides Earnings Guidance for the Year 2023

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

Price target increased by 8.0% to €31.61

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

Is MorphoSys (ETR:MOR) Weighed On By Its Debt Load?

MorphoSys AG Provides Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 12% to €25.94

Consensus EPS estimates upgraded to €6.45 loss

Does MorphoSys (ETR:MOR) Have A Healthy Balance Sheet?

Consensus estimates of losses per share improve by 12%

Price target increased by 7.3% to €19.64

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 27% to €18.25

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

Price target decreased to €24.05

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Price target decreased to €26.50

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023

MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to €32.45

MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

Price target decreased to €37.06

MorphoSys AG Announces Executive Changes

Consensus EPS estimates fall by 48%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022